0001104659-22-098951.txt : 20220909
0001104659-22-098951.hdr.sgml : 20220909
20220909170338
ACCESSION NUMBER: 0001104659-22-098951
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220907
FILED AS OF DATE: 20220909
DATE AS OF CHANGE: 20220909
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Hayon Yael
CENTRAL INDEX KEY: 0001817121
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33357
FILM NUMBER: 221236779
MAIL ADDRESS:
STREET 1: 2 SNUNIT STREET
STREET 2: SCIENCE PARK, POB 455
CITY: CARMIEL
STATE: L3
ZIP: 2161401
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Protalix BioTherapeutics, Inc.
CENTRAL INDEX KEY: 0001006281
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 650643773
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2 UNIVERSITY PLAZA
STREET 2: SUITE 100
CITY: HACKENSACK
STATE: NJ
ZIP: 07601
BUSINESS PHONE: 201-696-9345
MAIL ADDRESS:
STREET 1: 2 UNIVERSITY PLAZA
STREET 2: SUITE 100
CITY: HACKENSACK
STATE: NJ
ZIP: 07601
FORMER COMPANY:
FORMER CONFORMED NAME: ORTHODONTIX INC
DATE OF NAME CHANGE: 19980422
FORMER COMPANY:
FORMER CONFORMED NAME: EMBASSY ACQUISITION CORP
DATE OF NAME CHANGE: 19960124
4
1
tm2225460-8_4seq1.xml
OWNERSHIP DOCUMENT
X0306
4
2022-09-07
0
0001006281
Protalix BioTherapeutics, Inc.
PLX
0001817121
Hayon Yael
C/O PROTALIX BIOTHERAPEUTICS, INC.
2 SNUNIT STREET SCIENCE PARK, POB 455
CARMIEL
L3
2161401
ISRAEL
0
1
0
0
VP, Research & Development
Stock Options (Right to Buy)
1.03
2022-09-07
4
A
0
250000
0
A
2032-09-07
Common Stock
250000
250000
D
The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended.
Does not include options to purchase 129,771 shares of common stock at an exercise price equal to $3.73 per share that expire on July 5, 2030.
/s/ Eyal Rubin, POA
2022-09-09